SCHEMBL24532071

SCHEMBL24532071

Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1Nc1cc(-c2ccncc2)nc(-c2ccncc2)n1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 4/20 0.68
▸ APEX1 P27695 2/20 0.68
▸ MAPT P10636 2/20 0.68
▸ CSF1R P07333 2/20 0.61
▸ MAPK14 Q16539 6/20 0.61
▸ LCK P06239 5/20 0.61
▸ BRAF P15056 4/20 0.61
▸ KDR P35968 4/20 0.61
▸ TEK Q02763 1/20 0.61
▸ SRC P12931 4/20 0.60
▸ KIT P10721 3/20 0.60
▸ DDR1 Q08345 5/20 0.60
▸ DDR2 Q16832 5/20 0.60
▸ EPHB2 P29323 3/20 0.60
▸ HTT P42858 1/20 0.58
▸ ESYT2 A0FGR8 2/20 0.56
▸ NBAS A2RRP1 2/20 0.56
▸ CNOT1 A5YKK6 2/20 0.56
▸ TBKBP1 A7MCY6 2/20 0.56
▸ AGPS O00116 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24532063 0.89 POLB (0.67) POLBAPEX1MAPTCSF1RMAPK14
SCHEMBL5023651 0.86 POLB (0.68) POLBAPEX1MAPTCSF1RMAPK14
SCHEMBL22024705 0.85 PIKFYVE (0.75) POLBAPEX1MAPTCSF1RMAPK14
SCHEMBL22025503 0.84 POLB (0.63) POLBAPEX1MAPTCSF1RMAPK14
SCHEMBL22065428 0.83 POLB (0.58) POLBAPEX1MAPTCSF1RMAPK14
SCHEMBL22025300 0.82 BRAF (0.61) POLBAPEX1MAPTCSF1RMAPK14
SCHEMBL22066392 0.82 POLB (0.56) POLBAPEX1MAPTCSF1RMAPK14
SCHEMBL22025315 0.81 POLB (0.62) POLBAPEX1MAPTCSF1RMAPK14
SCHEMBL22025324 0.81 PIKFYVE (0.58) POLBAPEX1MAPTCSF1RMAPK14
SCHEMBL22024645 0.81 BRAF (0.68) POLBAPEX1MAPTCSF1RMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220194943-A1 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) 2022-06-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220194943-A1 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER EPHA1, EPHB2, EPHB1 POLB 4564/4885APEX1 3129/4885MAPT 1468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback